Full-year core operating income was broadly flat at $16.7 billion, it said in a statement.
(Reporting by Ludwig Burger; Editing by Paul Carrel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.52 CHF | -0.39% | -1.30% | -0.41% |
05:05pm | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
04:01pm | TotalEnergies: shareholders want to separate powers | CF |
BASEL (Reuters) - Swiss drugmaker Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023, following stagnation last year.
Full-year core operating income was broadly flat at $16.7 billion, it said in a statement.
(Reporting by Ludwig Burger; Editing by Paul Carrel)
1st Jan change | Capi. | |
---|---|---|
-0.41% | 204B | |
+27.71% | 676B | |
+23.58% | 554B | |
-7.59% | 349B | |
+14.61% | 318B | |
+6.43% | 291B | |
+2.96% | 210B | |
-10.02% | 194B | |
-12.04% | 144B | |
-8.59% | 142B |